Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects.
about
Review: Antiplatelet drugs: what comes next?Rivaroxaban in the contemporary treatment of acute coronary syndromes.In search of a better platelet ADP-receptor blocker.Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation.Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel.
P2860
Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Cangrelor increases the magnit ...... opidogrel-pretreated subjects.
@en
Cangrelor increases the magnit ...... opidogrel-pretreated subjects.
@nl
type
label
Cangrelor increases the magnit ...... opidogrel-pretreated subjects.
@en
Cangrelor increases the magnit ...... opidogrel-pretreated subjects.
@nl
prefLabel
Cangrelor increases the magnit ...... opidogrel-pretreated subjects.
@en
Cangrelor increases the magnit ...... opidogrel-pretreated subjects.
@nl
P2093
P2860
P356
P1476
Cangrelor increases the magnit ...... opidogrel-pretreated subjects.
@en
P2093
C M Hackeng
H J Bouman
J M Ten Berg
J W van Werkum
N Clappers
P2860
P2888
P304
P356
10.1007/BF03086246
P577
2009-05-01T00:00:00Z